Sciact
  • EN
  • RU

Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer Научная публикация

Журнал Mendeleev Communications
ISSN: 1364-551X , E-ISSN: 0959-9436
Вых. Данные Год: 2012, Том: 22, Номер: 6, Страницы: 287-289 Страниц : 3 DOI: 10.1016/j.mencom.2012.11.001
Авторы Rakitina Tatiana V. 1,2,3 , Zeifman Alexey A. 4,5 , Titov Ilya Yu. 4,5 , Svitanko Igor V. 5 , Lipkin Aleksey V. 2,3,6 , Stroylov Viktor S. 4,5 , Stroganov Oleg V. 4,5 , Novikov Fedor N. 4,5 , Chilov Ghermes G. 4,5
Организации
1 M. M. Shemyakin –Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russian Federation
2 Russian Research Center Kurchatov Institute, 123182 Moscow, Russian Federation
3 Moscow Institute of Physics and Technology (State University), 141700 Dolgoprudny, Moscow Region, Russian Federation
4 MolTech Ltd., 119992 Moscow, Russian Federation
5 N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991,Moscow, Russian Federation
6 A. N. Bach Institute of Biochemistry, Russian Academy of Sciences, 119071 Moscow, Russian Federation

Реферат: Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.
Библиографическая ссылка: Rakitina T.V. , Zeifman A.A. , Titov I.Y. , Svitanko I.V. , Lipkin A.V. , Stroylov V.S. , Stroganov O.V. , Novikov F.N. , Chilov G.G.
Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer
Mendeleev Communications. 2012. V.22. N6. P.287-289. DOI: 10.1016/j.mencom.2012.11.001 WOS Scopus OpenAlex
Идентификаторы БД:
Web of science: WOS:000312919100001
Scopus: 2-s2.0-84870356260
OpenAlex: W2027384673
Цитирование в БД:
БД Цитирований
OpenAlex 3
Scopus 3
Web of science 3
Альметрики: